{"id":"icotinib-plus-wbrt","safety":{"commonSideEffects":[{"rate":null,"effect":"Rash/dermatitis"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Radiation-related toxicity (from WBRT component)"}]},"_chembl":{"chemblId":"CHEMBL2087361","moleculeType":"Small molecule","molecularWeight":"391.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Icotinib selectively inhibits EGFR tyrosine kinase activity, preventing downstream proliferation signals in EGFR-mutant lung cancer cells. When combined with WBRT, the regimen targets both systemic disease and central nervous system metastases, with potential synergistic effects on brain tumor control. This combination approach addresses the challenge of treating patients with EGFR-mutant non-small cell lung cancer who develop brain metastases.","oneSentence":"Icotinib is an EGFR tyrosine kinase inhibitor that blocks epidermal growth factor receptor signaling in cancer cells, combined with whole-brain radiotherapy (WBRT) to treat brain metastases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:47:56.543Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer with EGFR mutations and brain metastases (in combination with whole-brain radiotherapy)"}]},"trialDetails":[{"nctId":"NCT04058704","phase":"PHASE3","title":"A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2018-07-20","conditions":"Non Small Cell Lung Cancer, Brain Metastases","enrollment":296},{"nctId":"NCT03754530","phase":"PHASE2","title":"Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2018-12-01","conditions":"Non-Small Cell Lung Cancer, Brain Metastases","enrollment":162},{"nctId":"NCT02714010","phase":"PHASE3","title":"EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-08","conditions":"Non-Small Cell Lung Cancer","enrollment":601},{"nctId":"NCT01724801","phase":"PHASE3","title":"Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer","status":"COMPLETED","sponsor":"Guangdong Association of Clinical Trials","startDate":"2012-10-14","conditions":"Brain Metastasis, Non Small Cell Lung Cancer","enrollment":176},{"nctId":"NCT02882984","phase":"PHASE3","title":"Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)","status":"UNKNOWN","sponsor":"Sichuan Provincial People's Hospital","startDate":"2015-03","conditions":"Stage IV EGFR Mutated NSCL With Brain Metastases","enrollment":325},{"nctId":"NCT01926171","phase":"PHASE4","title":"Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2013-06","conditions":"Non-small-cell Lung Cancer","enrollment":80},{"nctId":"NCT01514877","phase":"PHASE2","title":"Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Zhejiang Cancer Hospital","startDate":"2012-01","conditions":"Lung Cancer, Metastatic Cancer","enrollment":20},{"nctId":"NCT01516983","phase":"PHASE1, PHASE2","title":"Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation","status":"COMPLETED","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2011-12","conditions":"Non-small Cell Lung Cancer, Brain Metastases","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Commana","BPI-2009"],"phase":"marketed","status":"active","brandName":"Icotinib plus WBRT","genericName":"Icotinib plus WBRT","companyName":"Betta Pharmaceuticals Co., Ltd.","companyId":"betta-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Icotinib is an EGFR tyrosine kinase inhibitor that blocks epidermal growth factor receptor signaling in cancer cells, combined with whole-brain radiotherapy (WBRT) to treat brain metastases. Used for Non-small cell lung cancer with EGFR mutations and brain metastases (in combination with whole-brain radiotherapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}